Symphony Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Media Release".
SYMPHONY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Symphony Limited reported steep declines in FY26 with consolidated revenue falling 28% to ₹1,131 crore and standalone revenue dropping 35% to ₹765 crore. EBITDA collapsed 60% on both bases, with consol. EBITDA margin contracting sharply from 20.1% to 11.3%. The company blamed a high base effect from FY25, domestic channel inventory overhang, and geopolitical headwinds impacting Middle East exports. The Board proposed a final dividend of ₹5 per share, with total year-to-date payout at ~₹62 crore. Australia operations underwent a major balance sheet reset with impairments of ~₹298 crore (standalone) and ~₹259 crore (consolidated) to reflect structural market challenges in that region. The company also approved acquiring CTPL's intellectual property rights for ~₹23 crore and 100% equity in Bonaire USA LLC for ~₹30 crore, both funded from treasury, to bring key brands under the listed parent and improve U.S. business visibility. GSK China repaid ₹26 crore of its loan, reducing the outstanding balance to ₹4 crore from a peak of ₹60 crore.
Sharp revenue and profit declines signal operational stress, with the Australia impairment weighing on book value. However, the U.S. business remains profitable and the acquisitions may unlock value, while the dividend provides some investor reassurance despite the weak performance.